← All trials
NCT05201547
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Apr 15, 2022
- Primary completion
- Apr 30, 2026
- Completion date
- Oct 31, 2029
- First posted
- Jan 21, 2022
- Last posted
- Aug 10, 2022
- Enrollment
- 142
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- ARCAGY-GINECOLead sponsor
- GlaxoSmithKlineCollaborator
- University of Caen-NormandieOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.